ArticleParasites & vectors2017
The intravenous and oral pharmacokinetics of lotilaner in dogs.
Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Trial
- A randomised, blinded, controlled field study to assess the efficacy and safety of lotilaner tablets (Credelio™) in controlling fleas in client-owned dogs in European countries.Parasites & vectors · 2017Trial
- Laboratory evaluations of the immediate and sustained efficacy of lotilaner (Credelio™) against four common species of ticks affecting dogs in North America.Parasites & vectors · 2017Trial
- Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe.Parasites & vectors · 2017Trial
- Safety evaluation of lotilaner in dogs after oral administration as flavoured chewable tablets (Credelio™).Parasites & vectors · 2017Trial
- Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs.Parasites & vectors · 2017Trial
- Assessment of the onset of lotilaner (Credelio™) speed of kill of fleas on dogs.Parasites & vectors · 2017Trial
- Assessment of the speed of flea kill of lotilaner (Credelio™) throughout the month following oral administration to dogs.Parasites & vectors · 2017Trial
- Efficacy of lotilaner (CredelioParasites & vectors · 2026Article
- Comparative speed of kill of induced Ixodes scapularis infestations following treatment of dogs with endectocides containing either sarolaner (Simparica Trio™), afoxolaner (NexGardParasites & vectors · 2026Article
- Evaluation of efficacy and pharmacokinetics of novel fluralaner tablet formulation (WellPet™) in dogs.Frontiers in veterinary science · 2026Article
- Long-term safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs.Parasites & vectors · 2025Article
- A novel method for the determination of isoxazoline derivatives in plasma by ultra-high performance liquid chromatography-tandem mass spectrometry: validation and applicability to screening tests.Journal of veterinary research · 2025Article
- The Structural Basis of Binding Stability and Selectivity of Sarolaner Enantiomers forMolecules (Basel, Switzerland) · 2025Article
- Safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) in homozygous MDR1-mutant collie dogs.Parasites & vectors · 2025Article
- Demodex and the eye - A review.Indian journal of ophthalmology · 2025Review
- Fipronil prevents transmission of Lyme disease spirochetes.Parasitology · 2024Article
- Lotilaner Ophthalmic Solution, 0.25%, for the Treatment ofHealthcare (Basel, Switzerland) · 2024Review
- Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs.Parasites & vectors · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLotilaner is a new oral ectoparasiticide from the isoxazoline class developed for the treatment of flea and tick infestations in dogs. It is formulated as pure S-enantiomer in flavoured chewable tablets (Credelio™). The pharmacokinetics of lotilaner were thoroughly determined after intravenous and oral administration and under different feeding regimens in dogs.
methodsTwenty-six adult beagle dogs were enrolled in a pharmacokinetic study evaluating either intravenous or oral administration of lotilaner. Following the oral administration of 20 mg/kg, under fed or fasted conditions, or intravenous administration of 3 mg/kg, blood samples were collected up to 35 days after treatment. The effects of timing of offering food and the amount of food consumed prior or after dosing on bioavailability were assessed in a separate study in 25 adult dogs. Lotilaner blood concentrations were measured using a validated liquid chromatography/tandem mass spectrometry (LC-MS/MS) method. Pharmacokinetic parameters were calculated by non-compartmental analysis. In addition, in vivo enantiomer stability was evaluated in an analytical study.
resultsFollowing oral administration in fed animals, lotilaner was readily absorbed and peak blood concentrations reached within 2 hours. The terminal half-life was 30.7 days. Food enhanced the absorption, providing an oral bioavailability above 80% and reduced the inter-individual variability. Moreover, the time of feeding with respect to dosing (fed 30 min prior, fed at dosing or fed 30 min post-dosing) or the reduction of the food ration to one-third of the normal daily ration did not impact bioavailability. Following intravenous administration, lotilaner had a low clearance of 0.18 l/kg/day, large volumes of distribution V
conclusionsThe pharmacokinetic properties of lotilaner administered orally as a flavoured chewable tablet (Credelio™) were studied in detail. With a T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.